Thus, monoclonal antibodies exert both a direct anti-tumor effect by blocking and modulating the HER2 signaling and also an indirect effect by activating the immune system through the so-called antibody-dependent cellular cytotoxicity (ADCC) (Figure 1). Here, ERBB2 is linked to neoplasm.